Details for Patent: 9,446,135
✉ Email this page to a colleague
Which drugs does patent 9,446,135 protect, and when does it expire?
Patent 9,446,135 protects RYKINDO and is included in one NDA.
This patent has thirty-three patent family members in fourteen countries.
Summary for Patent: 9,446,135
| Title: | Risperidone sustained release microsphere composition |
| Abstract: | A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage. |
| Inventor(s): | Sun Kaoxiang, Liang Rongcai, Wang Qilin, Wang Wenyan, Liu Wanhui, Li Youxin |
| Assignee: | Shandong Luye Pharmaceutical Co., Ltd. |
| Application Number: | US14113738 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 9,446,135
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-001 | Jan 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Try a Trial | |||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Try a Trial | |||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-003 | Jan 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Try a Trial | |||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA IN ADULTS | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,446,135
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012248038 | ⤷ Try a Trial | |||
| Brazil | 112013027235 | ⤷ Try a Trial | |||
| Canada | 2832663 | ⤷ Try a Trial | |||
| China | 103338752 | ⤷ Try a Trial | |||
| China | 104127385 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
